Gene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
LEO orders Hitgen to discover new leads
Latest NewsIn a multi-year collaboration with LEO Pharma A/S, Chinese Hitgen is poised to discover novel small molecule leads for multiple therapeutic targets chosen by the Danish skin treatment specialist.
Acquisition: Thermo enters CMO world
BackgroundLab equipment giant Thermo Fisher Scientific Inc. is growing even bigger.
Uniqure’s new COO to oversee GMP
AppointmentsGene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
Vernalis receives next veto by FDA
Latest NewsBritish biotech company Vernalis has to deal with another Complete Response Letter by US authority FDA – this time regarding the New Drug Application for its cough and cold treatment CCP-08.
Hansa’s immunomodulatory enzyme does the job
Latest NewsSweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
Biosimilars labelling
OpinionEuropaBio has developed recommendations for changes to the Summary of Product Characteristics (SmPC) of biosimilars that would result in an enhanced level of transparency for the label.
TC Biopharm gets €4m Horizon2020 grant
Latest NewsThe Scottish biotech company TC Biopharm (TCB) has been awarded a €4m grant from the European Union’s Horizon 2020 programme.
Benefits and challenges in pharma innovation
OpinionWe are living in a world of cutting-edge science, which holds the potential to transform the landscape for patients living with common and rare diseases within the next five years. This is of particular importance as we face a demographic evolution that will see an already-aging population expand significantly and rapidly across the globe.
Zealand taps US market
Latest NewsDanish diabetes biotech Zealand Pharma has started its initial public offering in the US at Nasdaq Global Select Market. It plans to raise US$75m to fund clinical trails.
Autolus: Accelerating T-cell products
AppointmentsIn preparation for the development and commercialisation of Autolus’ T-cell products, the London based company announced four new senior leadership appointments.